Is There an Oral Retatrutide Pill? Tablets, Drops and Nasal Spray

No, there's no oral retatrutide. Eli Lilly doesn't make a retatrutide pill, capsule, drop or nasal spray, and as of October 31, 2026 not one of the 33 retatrutide studies on ClinicalTrials.gov gives the drug by mouth or through the nose. Every trial so far has injected it, mostly as a once-weekly shot under the skin, including all six Phase 3 trials that have reported. The "reta pills" and drops sold online (and anything called a GLP-3 pill, since GLP-3 is only a nickname for retatrutide) have never been tested in people, so nobody can tell you how much of them, if any, reaches your blood.

Retatrutide is still in Phase 3 trials and no approved version exists yet. Lilly's October 2026 FAQ says it "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use."

Is there an oral retatrutide pill in any trial?

We checked ClinicalTrials.gov again on October 31, 2026, and the count hadn't moved: 33 records, from a single-dose safety study that finished in 2019 through the Phase 3 programs, plus one Phase 2 listing from a sponsor other than Lilly. Here's how those records say the drug goes in.

The word "orally" does appear in 3 of the records. Each time it describes another drug given alongside retatrutide to check for interactions (a contraceptive pill, metoprolol, and a mix of midazolam, warfarin and caffeine). Retatrutide itself was injected in all three.

Lilly's FAQ, last updated October 2026, puts it in one line: "In clinical trials, retatrutide is taken as a once-weekly subcutaneous injection." Every Phase 3 result so far comes from that route, from the 28.3% average weight loss on 12 mg over 80 weeks in TRIUMPH-1 to the October 28 head-to-head against Ozempic 2 mg.

Why retatrutide is a weekly shot

Retatrutide is a peptide, a chain of 39 amino acids according to the FDA's substance record, with a fatty acid chain attached. Swallow a peptide and your stomach treats it much like protein from food. Very little gets through intact. The best measure comes from semaglutide, a similar peptide with a similar fatty acid: even with an absorption enhancer, at most about 1 in 100 molecules from a Rybelsus tablet reaches the bloodstream, per its FDA label.

Under the skin, the numbers flip. The table sets the share of a dose that reaches the blood (absolute bioavailability) side by side, using the FDA labels. Everything except the two retatrutide rows is class evidence, not retatrutide data.

That study compared injection sites and, in a second part, gave a dose into a vein, the comparison an absolute bioavailability figure is usually calculated from. Lilly hasn't posted its results.

For semaglutide, the fatty acid is also why one shot lasts a week: its label credits the long half-life mainly to binding with albumin, a protein in the blood, which the fatty acid makes possible. For retatrutide, the Phase 1b trial in The Lancet measured a half-life of about 6 days, and Lilly Medical Information gives a time to peak of 12 to 72 hours after a dose, which it says together support once-weekly dosing. Our retatrutide half-life page has the full timeline.

What it took to turn semaglutide into a pill

Semaglutide is the one peptide GLP-1 drug that made it to a tablet, and its FDA labels show what that cost. Each tablet contains an absorption enhancer, salcaprozate sodium (SNAC), and absorption happens mostly in the stomach. That's where the 0.4% to 1% (Rybelsus) and 1% to 2% (Ozempic and Wegovy tablets) in the table come from.

The rules for taking it are strict: one tablet a day, in the morning on an empty stomach, with up to 4 ounces of plain water, then no food, drinks or other pills for at least 30 minutes. The Rybelsus and Ozempic tablet label also says not to split, crush, chew or dissolve it in any solution.

The doses make the gap concrete. These are pairings the FDA labels themselves make, with the weekly totals worked out:

The Wegovy label puts average steady blood levels at about 77 nmol/L on the 25 mg daily tablet and 75 nmol/L on the 2.4 mg weekly shot, and predicts similar levels in people without type 2 diabetes, with more variation on the tablet. That's roughly 73 times more semaglutide swallowed each week (175 mg against 2.4 mg) to match what the shot delivers. In people with type 2 diabetes, levels on the tablet ran lower, and the label warns that some of them may end up below an effective level.

What's sold as reta pills, capsules, drops and nasal spray

Outside Lilly's trials, anything sold as a retatrutide pill, capsule, sublingual drop (held under the tongue) or nasal spray comes from an unapproved seller. None has a published study in people, and none appears among the 33 trial records above. A plain capsule is a shell around powder, and it doesn't stop the stomach from breaking a peptide down.

Any weight-loss number quoted for these products has to come from the injection trials. The largest Phase 2 figure, 24.2% at 48 weeks on 12 mg, came from people injecting retatrutide once a week in the NEJM trial. It tells you nothing about drops.

The approved pills explain why that matters. Semaglutide gets into the blood through the stomach with SNAC's help, and its label forbids dissolving the tablet in liquid. A dropper bottle of dissolved peptide held under the tongue, or a nasal spray, has no published absorption data and no enhancer anyone has shown to work.

Every product labeled retatrutide outside Lilly's trials is unapproved, whatever form it comes in. The FDA says retatrutide can't be used in compounding under federal law, and its August 24, 2026 warning letter to one seller called a product named "GLP-3 Reta (Retatrutide)" an unapproved new drug. Our page on whether retatrutide is legal covers what that means for buyers. Regulators have also found that labels and contents don't always match. In a September 14, 2026 alert, Australia's Therapeutic Goods Administration (TGA) reported testing a vial sold as retatrutide after a buyer was hospitalized with uncontrollable vomiting and a torn esophagus. It held no retatrutide, and it did hold semaglutide at about 8 times the level in approved products. In a June 19, 2026 alert, Victoria's health department linked 6 cases of acute liver injury since January 2026 to products labeled Retatrutide, possibly from a contaminant, and says all such products are at risk.

If you're weighing sellers of the injectable form anyway, our guide to retatrutide for sale explains what a batch-specific test report has to show, and our where to buy retatrutide page covers the red flags.

Do retatrutide pills or drops work?

Nobody knows, including the people selling them. For a pill or drop to do anything, enough intact retatrutide has to reach your blood, and no one has published a measurement of whether any does.

For a sense of scale, take semaglutide as a stand-in, which is a big assumption. If a retatrutide tablet were absorbed as well as the Wegovy tablet, matching the 12 mg weekly shot used in TRIUMPH-1 would take about 875 mg a week, or 125 mg every day. That's arithmetic, not a dose. No such tablet has been made or tested, and a drop or capsule with no tested enhancer has no reason to do better than semaglutide does with one.

Drinking the injectable solution or holding it under your tongue, which some people ask about, has no absorption data either.

Our read: on the semaglutide numbers, a peptide swallowed or held under the tongue without a tested enhancer is unlikely to reach useful levels, and the TGA test shows the label may not tell you what's inside anyway.

Will Lilly make an oral retatrutide?

Nothing Lilly has published points that way. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. Either way, every trial behind the filing used the weekly injection, there's no oral retatrutide study on ClinicalTrials.gov, and Lilly's pipeline page lists retatrutide only as a large molecule, with no oral version.

Lilly's pill is a different molecule. Foundayo (orforglipron), approved by the FDA on April 1, 2026, is a small molecule rather than a peptide. Its label gives a molecular weight of 902.0 g/mol for orforglipron calcium, against 4113.58 g/mol for semaglutide on the Rybelsus label, so it's about a fifth of the size. It needs no enhancer: its label gives an absolute bioavailability of 77% and says to take it once daily, with or without food.

Foundayo works on the GLP-1 receptor only, while retatrutide works on three (GIP, GLP-1 and glucagon). In Foundayo's ATTAIN-1 trial, people on the highest dose who stayed on treatment lost 12.4% of their weight over 72 weeks against 0.9% on placebo, per Lilly's April 1 release; across everyone randomized, the label gives 11.1% for the 17.2 mg dose against 2.1% on placebo. In TRIUMPH-1, the 12 mg retatrutide dose averaged 28.3% over 80 weeks for people who stayed on treatment, and 25.0% across everyone randomized (the NEJM paper's primary result), against 2.2% and 3.9% on placebo in the two analyses. Different trials, different people, so treat the gap as a rough guide.

Our read: an oral retatrutide would need its own formulation work and its own trials, and none of that is on the public record today.

If you want a pill now

These are the GLP-1 pills with FDA approval, as of October 2026. The self-pay prices are the makers' published cash prices, re-checked on October 31, 2026.

None of them works on all three of retatrutide's receptors, and the weight-loss numbers aren't directly comparable. Our retatrutide vs semaglutide comparison sets the Wegovy pill and shots against retatrutide's trial results, and the broader retatrutide vs GLP-1 page covers the other approved drugs. Our GLP-3 explainer covers where that nickname came from.

If the needle is what's putting you off, our guide on how to inject retatrutide goes through needle length and sites, and the how to take retatrutide hub covers the rest of the routine. Before approval, the legal ways to get retatrutide itself are a trial or, for a narrow group of people with severe obesity, Lilly's expanded access program. Our retatrutide clinical trials page covers how to find a trial.

If you've already used an oral product sold as retatrutide and feel unwell, keep the bottle or vial and show it to your doctor, since what's printed on it may not be what's inside.